Societal cost of subcutaneous and intravenous trastuzumab for HER2-positive breast cancer - An observational study prospectively recording resource utilization in a Swedish healthcare setting
详细信息 查看全文
- 作者：Sara Olofssona ; b ; so@ihe.se" class="auth_mail" title="E-mail the corresponding author ; Hanna Norrlida ; hn@ihe.se" class="auth_mail" title="E-mail the corresponding author ; Eva Karlssonc ; eva.u.karlsson@skane.se" class="auth_mail" title="E-mail the corresponding author ; Ulla Wilkingd ; ulla.wilking@ki.se" class="auth_mail" title="E-mail the corresponding author ; Gunnel Ragnarson Tennvalla ; grt@ihe.se" class="auth_mail" title="E-mail the corresponding author
- 关键词：HER2-positive breast cancer ; Trastuzumab ; Subcutaneous ; Intravenous ; Resource use ; Societal cost
- 刊名：The Breast
- 出版年：2016
- 出版时间：October 2016
- 年：2016
- 卷：29
- 期：Complete
- 页码：140-146
- 全文大小：489 K
文摘
- •
Subcutaneous administration of trastuzumab require less nurse time compared to intraveous administration.
- •
Subcutaneous administration of trastuzumab requires less time spent by the patient and peer at the hospital.
- •
A majority of patients receiving trastuzumab prefer to receive their treatment by subcutaneous administration.